The Company and a Summary of its Significant Accounting Policies - Additional Information (Details)
|
|
12 Months Ended |
Aug. 29, 2019 |
Dec. 31, 2021
USD ($)
Warrant
Revenue_Stream
Segment
$ / shares
shares
|
Dec. 31, 2020
USD ($)
shares
|
Dec. 31, 2019
USD ($)
shares
|
| The Company and Summary of its Significant Accounting Policies [Line Items] |
|
|
|
|
| Conversion ratio of reverse stock split |
0.5
|
|
|
|
| Description of reverse stock split of common stock |
|
one-for-two
|
|
|
| Net change in net cash used in operating activities |
|
$ 0
|
|
|
| Depreciation expense |
|
997,000
|
$ 486,000
|
$ 89,000
|
| Gross assets |
|
6,174,000
|
3,418,000
|
|
| Accumulated amortization |
|
100,000
|
10,000
|
|
| Disposal of plant or equipment |
|
100,000
|
100,000
|
0
|
| Impairment losses |
|
0
|
0
|
0
|
| Sweep account |
|
100,100,000
|
|
|
| Insured amount by FDIC |
|
250,000
|
|
|
| Cash held in excess of FDIC limit |
|
$ 60,200,000
|
|
|
| Number of revenue streams | Revenue_Stream |
|
2
|
|
|
| Short-term deferred revenue |
|
$ 1,380,000
|
905,000
|
|
| Long-term deferred revenue |
|
0
|
639,000
|
|
| Accounts receivable |
|
$ 3,847,000
|
1,480,000
|
|
| Number of operating segments | Segment |
|
1
|
|
|
| Stock-based compensation expense |
|
$ 13,300,000
|
5,000,000.0
|
$ 1,300,000
|
| Compensation cost related to non-vested awards not yet recognized |
|
$ 38,400,000
|
|
|
| Weighted average term expected to be recognized |
|
2 years 9 months 29 days
|
|
|
| Level 1 | Restricted Cash |
|
|
|
|
| The Company and Summary of its Significant Accounting Policies [Line Items] |
|
|
|
|
| Letters of credit |
|
$ 3,000,000.0
|
$ 0
|
|
| Conversion of Preferred Stock |
|
|
|
|
| The Company and Summary of its Significant Accounting Policies [Line Items] |
|
|
|
|
| Anti-dilutive equity instruments excluded from diluted net loss per common share | shares |
|
|
|
615,385
|
| Common Stock Warrants |
|
|
|
|
| The Company and Summary of its Significant Accounting Policies [Line Items] |
|
|
|
|
| Anti-dilutive equity instruments excluded from diluted net loss per common share | shares |
|
734,329
|
3,885,311
|
4,200,497
|
| Stock Options |
|
|
|
|
| The Company and Summary of its Significant Accounting Policies [Line Items] |
|
|
|
|
| Anti-dilutive equity instruments excluded from diluted net loss per common share | shares |
|
|
|
443,547
|
| Stock Options and Restricted Stock Units |
|
|
|
|
| The Company and Summary of its Significant Accounting Policies [Line Items] |
|
|
|
|
| Anti-dilutive equity instruments excluded from diluted net loss per common share | shares |
|
2,704,035
|
2,112,980
|
|
| Assay Revenue |
|
|
|
|
| The Company and Summary of its Significant Accounting Policies [Line Items] |
|
|
|
|
| Accounts receivable gross |
|
$ 3,600,000
|
$ 1,000,000.0
|
|
| Contract Revenue |
|
|
|
|
| The Company and Summary of its Significant Accounting Policies [Line Items] |
|
|
|
|
| Accounts receivable |
|
$ 200,000
|
500,000
|
|
| Minimum |
|
|
|
|
| The Company and Summary of its Significant Accounting Policies [Line Items] |
|
|
|
|
| Useful life of the assets |
|
2 years
|
|
|
| Remaining lease term |
|
2 years
|
|
|
| Minimum | Stock Options |
|
|
|
|
| The Company and Summary of its Significant Accounting Policies [Line Items] |
|
|
|
|
| Requisite service period |
|
3 years
|
|
|
| Minimum | Restricted Stock Units |
|
|
|
|
| The Company and Summary of its Significant Accounting Policies [Line Items] |
|
|
|
|
| Requisite service period |
|
2 years
|
|
|
| Maximum |
|
|
|
|
| The Company and Summary of its Significant Accounting Policies [Line Items] |
|
|
|
|
| Useful life of the assets |
|
5 years
|
|
|
| Remaining lease term |
|
10 years
|
|
|
| Extend lease term |
|
10 years
|
|
|
| Maximum | Stock Options |
|
|
|
|
| The Company and Summary of its Significant Accounting Policies [Line Items] |
|
|
|
|
| Requisite service period |
|
4 years
|
|
|
| Maximum | Restricted Stock Units |
|
|
|
|
| The Company and Summary of its Significant Accounting Policies [Line Items] |
|
|
|
|
| Requisite service period |
|
4 years
|
|
|
| Amortization of Laboratory Equipment Acquired under Finance Leases |
|
|
|
|
| The Company and Summary of its Significant Accounting Policies [Line Items] |
|
|
|
|
| Depreciation expense |
|
$ 100,000
|
10,000
|
$ 0
|
| Assets Recorded under Finance Leases |
|
|
|
|
| The Company and Summary of its Significant Accounting Policies [Line Items] |
|
|
|
|
| Gross assets |
|
400,000
|
300,000
|
|
| Accumulated amortization |
|
$ 100,000
|
$ 10,000
|
|
| SPAC Warrants |
|
|
|
|
| The Company and Summary of its Significant Accounting Policies [Line Items] |
|
|
|
|
| Warrants expiration period |
|
5 years
|
|
|
| Number of warrants entitle holder to purchase one share | Warrant |
|
4
|
|
|
| Number of shares issued for each warrant | shares |
|
0.25
|
|
|
| Exercise price of warrant | $ / shares |
|
$ 23.00
|
|
|
| SPAC Warrants | Public Offering |
|
|
|
|
| The Company and Summary of its Significant Accounting Policies [Line Items] |
|
|
|
|
| Warrants issued to purchase common stock | shares |
|
14,375,000
|
|
|
| SPAC Warrants | Private Placement Offering |
|
|
|
|
| The Company and Summary of its Significant Accounting Policies [Line Items] |
|
|
|
|
| Warrants issued to purchase common stock | shares |
|
561,250
|
|
|